Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.70 |
| ▸ | MMP13 | P45452 | 16/20 | 0.70 |
| ▸ | MMP9 | P14780 | 7/20 | 0.62 |
| ▸ | MMP1 | P03956 | 7/20 | 0.62 |
| ▸ | MMP2 | P08253 | 8/20 | 0.57 |
| ▸ | MMP14 | P50281 | 5/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264607 | 0.93 | ADAM17 (0.81) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6263687 | 0.91 | ADAM17 (0.71) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6263125 | 0.87 | ADAM17 (0.67) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6265670 | 0.87 | ADAM17 (0.80) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6263837 | 0.87 | ADAM17 (0.64) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6269109 | 0.86 | ADAM17 (0.66) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6267548 | 0.85 | ADAM17 (0.65) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6266856 | 0.84 | MMP13 (0.68) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL7365665 | 0.83 | ADAM17 (0.82) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6264635 | 0.83 | ADAM17 (0.82) | ADAM17MMP13MMP9MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
| US-6753337-B2 | INHIBITORS OF TNF-ALPHA CONVERTING ENZYME; TREATMENT OF ARTHRITIS, INFLAMMATION, INFLAMMATORY BOWEL DISEASE ETC, | WYETH HOLDINGS CORPORATION | 2004-06-22 | — | — | US | disclosed |
| EP-1252143-A1 | METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES | American Cyanamid Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020099035-A1 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives | WYETH HOLDINGS CORPORATION | 2002-07-25 | — | — | US | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001055112-A1 | METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP9 3/4885 |
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP9 3/4885 |
| US-20020099035-A1 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives | MMP25, ADAMTS5, MMP9 | ADAM17 4/4885MMP13 22/4885MMP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.